SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as it rebounds, liquidating a significant amount of short positions, fueling discussions about potential catalysts like U.S.-China trade talks and possible leaked big news. The community is actively watching for a breakout above key resistance levels, with some anticipating a rapid move towards new all-time highs. Bullish sentiment appears to be building, drawing comparisons to previous rallies and sparking debates about market manipulation and long-term investment strategies.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the crypto market shows strength, potentially fueled by optimism around US-China trade agreements and anticipation of future rate cuts. Community members are closely watching technical indicators and anticipating a significant price surge, with some setting ambitious targets for the near future. Bullish sentiment seems to be growing, with many traders expressing confidence in Ethereum's potential for substantial gains.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy ($MSTR) is trending as Bitcoin's price movements and potential impact on the stock are actively discussed by the community. Chatter revolves around MicroStrategy's potential for growth relative to Bitcoin, with some highlighting news about institutional buying and technical analysis suggesting possible bullish setups. Some traders are actively trading options on MSTR, while others express concerns about dilution and NAV.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with community members actively discussing potential positive outcomes and a possible run-up to new highs. Optimism is fueled by speculation of a 'triple beat' on revenue, EBITDA, and EPS, as well as potential rate cuts and the possibility of S&P 500 inclusion.  Some traders are wary of a potential post-earnings dip, while others remain bullish on the company's long-term prospects.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community anticipates a breakout, with some eyeing the $200 mark and beyond. Discussions revolve around potential catalysts like a China trade deal and a Solana ETF, while meme coins built on Solana, like $WAGMI, $UPDOG, and $BOOCOIN, are also gaining traction.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending amid discussions about a potential deal with Australia's Larvotto Resources and the implications for U.S. antimony supply. Community members are debating the deal's valuation, potential government involvement, and UAMY's strategic position as a domestic supplier. Bullish sentiment persists due to UAMY's existing contracts and potential growth, despite deal uncertainties and sector volatility.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as social media mentions draw comparisons to previous meme stock rallies, particularly with *another* stock experiencing high short interest. The community is actively discussing potential short squeezes, options activity, and the influence of key figures. Some traders express frustration with perceived market manipulation and are debating the company's long-term prospects.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express strong conviction in the project's long-term growth and potential within the Solana ecosystem. The community emphasizes holding through market volatility and building a decentralized future. Discussions also highlight how to purchase WAGMI, with community members providing tutorials and guidance.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as discussions highlight its privacy features, limited supply, and potential as a hedge against Bitcoin. Community members are pointing to its upcoming halving and comparing it favorably to other cryptocurrencies, with some anticipating a continued surge. The focus remains on its unique attributes within the broader crypto market and its potential for significant growth.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors react to news of a multi-year, multi-million dollar partnership with Lumen Technologies to boost enterprise AI. Community discussions revolve around the significance of this deal for Palantir's commercial growth and its role in the AI infrastructure landscape, with some highlighting the potential for a breakout while others question the valuation. Broader market sentiment and upcoming earnings are also contributing to the stock's current buzz.

statis crypto Watchlist

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IMUNON, Inc. (IMNN) said on Wednesday its first patient has been dosed with the firm’s lead candidate, IMNN-001, as part of a late-stage trial evaluating the drug in the treatment of women with newly diagnosed advanced ovarian cancer.Shares of the company traded 4% higher in morning trade at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMNN">IMUNON</a> jumped from ‘bearish’ to ‘neutral’ over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_9_43_26_AM_png_dc891d230b.webp" alt="IMNN's Sentiment Meter and Message Volume as of 10 a.m. ET on July 30, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>IMNN's Sentiment Meter and Message Volume as of 10 a.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company is undervalued.<stembedurl>https://stocktwits.com/ConcernedCitizen23/message/623007565</stembedurl>The late-stage <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.imunon.com/news-releases/news-release-details/imunon-announces-first-patient-dosed-phase-3-ovation-3-study">study</a> is aimed at assessing the safety and efficacy of IMNN-001 plus standard of care neoadjuvant and adjuvant chemotherapy of Paclitaxel and Carboplatin compared to standard of care chemotherapy alone.The primary endpoint of the study is overall survival or lengthening the lifespan of patients.The study will also check secondary endpoints such as surgical response score, chemotherapy response score, clinical response, and time to second-line treatment.“We have great urgency around this program because patients do not have any other options besides the standard of care, which includes neoadjuvant and adjuvant chemotherapy and surgery,” CEO Stacy Lindborg said.According to IMUNON, epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every year, and approximately 70% are diagnosed in advanced Stage III/IV, the company said.Earlier this month, IMUNON completed a reverse stock split of its issued and outstanding common stock at a ratio of 1:15 to meet the minimum bid price requirement for continued listing on the Nasdaq.IMNN stock is down by 43% this year and by about 84% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/humana-announces-upbeat-earnings-raised-guidance/choXGmPR5zr">Humana Stock Gains On Upbeat Earnings And Raised Guidance, Draws Retail Praise</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued

The trial is evaluating IMNN-001 in the treatment of women with newly diagnosed advanced ovarian cancer. 

Equity

The trial is evaluating IMNN-001 in the treatment of women with newly diagnosed advanced ovarian cancer. 


Imunon hit its highest levels in nearly three years Tuesday, fueled by its announcement to present Phase 2 OVATION 2 study immune biomarker data at the European Society for Medical Oncology Gynaecological Cancers Congress 2025.The accepted abstract presents the results of IMNN-001, an IL-12 gene therapy developed from Imunon's TheraPlas platform, used in conjunction with neoadjuvant and adjuvant chemotherapy treatments for newly diagnosed, advanced ovarian cancer patients.Imunon shares surged 95.69% to close at $2.27 on May 27, before pulling back 23.35% in after-hours trading to $1.74.Premal H. Thaker, the chair of the Ovation 2 and 3 study, will deliver the presentation at the June 19–21 Vienna-based congress.The announcement follows recent news that new Ovation 2 data will also be featured in an oral presentation at the 2025 ASCO Annual Meeting and published in Gynecologic Oncology.&nbsp;These results showed meaningful increases in overall and progression-free survival for the IMNN-001 treatment group, with a median 13-month improvement in overall survival.CEO Stacy Lindborg called the data “remarkable” and said the growing interest from EU and Latin American researchers reinforces confidence in the company’s Phase 3 Ovation 3 trial and regulatory ambitions.&nbsp;The Phase 3 Ovation 3 trial, which recently initiated its first two sites, will evaluate IMNN-001 plus chemotherapy versus chemotherapy alone in patients with Stage IIIC or IV epithelial ovarian cancer.&nbsp;The primary endpoint is overall survival.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,554% surge in 24-hour message volume.One user commented that anyone worried about the after-hours drop should note that the stock behaved similarly last Friday, followed by a strong run the next day.&nbsp;<stembedurl>https://stocktwits.com/NFD2/message/615992363</stembedurl>Another user highlighted the possibility of an upcoming press release announcing a major partnership with a big pharmaceutical company to support funding and potential licensing or commercialization deals, citing CEO comments from recent weeks.<stembedurl>https://stocktwits.com/gourmetmacncheese/message/615991264</stembedurl>The stock has risen 116% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Imunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News Soon

The data highlights promising results for IMNN-001, an IL-12 gene therapy for advanced ovarian cancer, boosting investor optimism ahead of its Phase 3 trial.

Retail buzz around Imunon rose sharply Thursday after the clinical-stage biotech company said it will no longer pursue a previously planned public offering.&nbsp;Imunon formally requested to retract its Form S-1 registration with the SEC after initially registering the document on April 4.The biotech firm's shares rose 4.1% to $0.42 on Thursday and surged another 15.5% in after-hours trading to $0.48.The news follows a first-quarter (Q1) financial update, which showed that Imunon decreased its net loss from $4.9 million last year to $4.1 million.Imunon reported a per-share loss of $0.28, below the consensus estimate of $0.36.R&amp;D cost reductions totaling $1.1 million drove an 18% decrease in operating expenses, bringing the total to $4.1 million.&nbsp;The decline was driven by spending reductions on the Ovation 2 study, the PlaCCine DNA vaccine trial, and platform development activities.Employee-related costs&nbsp;increased, causing general and administrative expenses to rise slowly to $2.0 million from $1.7 million last year, although lower legal fees helped partially offset this increase.The operating activities required $2.8 million in cash, a reduction of more than half compared to the $5.9 million used in Q1 2024.As of quarter-end, Imunon maintained $2.9 million in cash reserves and projects that these funds will support operations until late Q2 2025.CEO Stacy Lindborg highlighted clinical advancements, including the Ovation 3 pivotal study and ongoing results from the Ovation 2 trial, which showed that the DNA-based immunotherapy IMNN-001 increased progression-free and overall survival rates among patients newly diagnosed with ovarian cancer.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,120% surge in 24-hour message volume.One user suggested the move implies management may have “a much better option for funding,” citing recent earnings call comments from the CEO about active financing and partnership discussions.&nbsp;<stembedurl>https://stocktwits.com/ItTakesItAll/message/615624018</stembedurl>Another user called the update “great news,” pointing to the company’s low float.<stembedurl>https://stocktwits.com/ItTakesItAll/message/615621205</stembedurl>The stock has declined 60.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of scientist hand inoculating an agar plates with bacteria in microbiology lab | Image source: Getty Images

Retail Bulls Cheer Imunon’s Pullback From Public Offering, Citing ‘Much Better Funding Options’

Shares jumped 15.5% after hours, as retail traders pointed to “much better funding options” hinted at during the firm’s recent earnings call.

Earnings Outlook For Imunon

Equities Analysts Issue Forecasts for Imunon, Inc.'s Q1 2024 Earnings (NASDAQ:IMNN)

Imunon, Inc. (NASDAQ:IMNN - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 earnings estimates for Imunon in a research report issued to clients and investors on Monday...

Imunon, Inc. (NASDAQ:IMNN) Short Interest Down 8.6% in March

Imunon, Inc. (NASDAQ:IMNN - Get Free Report) saw a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 449,100 shares, a drop of 8.6% from...

Imunon price target raised by $1 at H.C. Wainwright, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Q4 2023 Imunon Inc Earnings Call Transcript

Imunon sees cash runway into 4Q24

Imunon reports 2023 EPS ($2.16) vs. ($5.03) last year

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Imunon Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$4.85
Prev Close	$4.91
Open	$4.91
Dividend Yield	0.00%
50-Day Moving Average	$5.50
Beta	0.52
Avg. Volume	138,293.71
PE Ratio	-0.36

52-Week High	$41.22
52-Week Low	$4.60
Market Capitalization	$12.23M
EPS (Annual)	-$21.10
Price to Book	3.60
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

IMNN
Imunon Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IMNN News

IMNNImunon Inc